Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

319
Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
319
Pre-Procedural Guidelines for Assessing Blood Pressure01:10

Pre-Procedural Guidelines for Assessing Blood Pressure

744
Accurate blood pressure assessment is crucial for diagnosing and managing various health conditions. To ensure the reliability of these measurements, healthcare professionals must adhere to standardized pre-procedural guidelines. These guidelines enhance patient safety and improve the overall quality of healthcare. The following steps are essential for obtaining accurate and consistent blood pressure readings, from using the appropriate tools to ensuring effective communication with the...
744
Hypertension and Regulation of Blood Pressure01:18

Hypertension and Regulation of Blood Pressure

3.5K
Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
3.5K
Hypertension I: Introduction01:28

Hypertension I: Introduction

530
Hypertension is a widespread, long-term medical condition where blood pressure in the arteries remains elevated. It is characterized by systolic blood pressure readings of 130 mm Hg or above or diastolic blood pressure (DBP) readings of 80 mm Hg or higher. Unmanaged hypertension poses significant health risks, making the distinction between primary (or essential) hypertension and secondary hypertension crucial, as their management and implications vary.Primary HypertensionPrimary hypertension,...
530
Hypertension V: Nursing Management01:23

Hypertension V: Nursing Management

227
The nursing management of hypertension involves accurately assessing symptoms, making a comprehensive nursing diagnosis, collaborating with patients to set goals, and implementing targeted interventions to mitigate the condition's impact and improve patient well-being.Comprehensive AssessmentThe initial step in nursing care for hypertension involves a thorough patient assessment. It includes evaluating symptoms such as headaches, dizziness, blurred vision, and previous hypertension episodes.
227
Errors occurring during blood pressure monitoring01:25

Errors occurring during blood pressure monitoring

1.2K
Blood pressure monitoring is a crucial clinical procedure in diagnosing and managing various cardiovascular conditions. Despite its significance, the accuracy of blood pressure measurements can be compromised by multiple factors, potentially leading to either falsely high or low readings. These inaccuracies are critical as they can significantly impact patient care. So, it is vital to understand these challenges deeply and adopt strategic approaches to minimize errors.
Several factors...
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Resistant Hypertension Variants Link to Hyperaldosteronism and Potassium Levels.

Hypertension (Dallas, Tex. : 1979)·2026
Same author

Leadership, Informatics Expertise, and Resources: Determinants of Institutional Data Sharing in the National Clinical Cohort Collaborative (N3C).

AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science·2026
Same author

A Primary Open-Angle Glaucoma Locus Near Transcription Factor <i>PRRX1</i> Identified in the Million Veteran Program.

Ophthalmology science·2026
Same author

Impact of Sociodemographic Variables on Physical Therapists' Documentation of Physical Activity Levels.

Archives of physical medicine and rehabilitation·2026
Same author

Emerging role of artificial intelligence in necrotizing enterocolitis and implementation challenges.

Pediatric research·2026
Same author

Shared Genetic Architecture Between Kidney Function and Alzheimer Disease Across Ancestries.

medRxiv : the preprint server for health sciences·2026

Related Experiment Video

Updated: Dec 10, 2025

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis
07:51

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis

Published on: September 26, 2018

7.9K

Optimizing identification of resistant hypertension: Computable phenotype development and validation.

Caitrin W McDonough1, Kyle Babcock1, Kristen Chucri1

  • 1Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Gainesville, Florida, USA.

Pharmacoepidemiology and Drug Safety
|August 27, 2020
PubMed
Summary
This summary is machine-generated.

Researchers developed computable phenotypes for resistant hypertension (RHTN) and stable controlled hypertension (HTN) using electronic health record data. These validated algorithms enable future research into hypertension epidemiology and drug use.

Keywords:
computable phenotypeselectronic health recordshypertensionpharmacoepidemiologyresistant hypertension

More Related Videos

In Silico Clinical Trials for Cardiovascular Disease
09:09

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

2.1K
In Vivo Modeling of the Morbid Human Genome using Danio rerio
12:31

In Vivo Modeling of the Morbid Human Genome using Danio rerio

Published on: August 24, 2013

21.1K

Related Experiment Videos

Last Updated: Dec 10, 2025

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis
07:51

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis

Published on: September 26, 2018

7.9K
In Silico Clinical Trials for Cardiovascular Disease
09:09

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

2.1K
In Vivo Modeling of the Morbid Human Genome using Danio rerio
12:31

In Vivo Modeling of the Morbid Human Genome using Danio rerio

Published on: August 24, 2013

21.1K

Area of Science:

  • Health Informatics
  • Clinical Research
  • Cardiovascular Disease

Background:

  • Electronic Health Records (EHRs) are crucial for identifying patient cohorts for research.
  • Computable phenotypes are essential for leveraging EHR data to define specific patient characteristics.
  • Researching complex conditions like hypertension requires accurate patient identification methods.

Purpose of the Study:

  • To develop and validate computable phenotype algorithms for resistant hypertension (RHTN) and stable controlled hypertension (HTN).
  • To adapt these algorithms to the National Patient-Centered Clinical Research Network (PCORnet) Common Data Model (CDM).
  • To enable large-scale epidemiological and drug utilization studies in hypertension.

Main Methods:

  • Adapted existing phenotype algorithms for RHTN and stable controlled HTN to the PCORnet CDM.
  • Validated algorithms using manual chart review of 425 patient records by two independent reviewers.
  • Assessed phenotype precision using positive predictive value (PPV) and interrater reliability (IRR).

Main Results:

  • Identified 24,926 patients with RHTN and 19,100 with stable controlled HTN from 156,730 hypertension patients.
  • Achieved high PPV for RHTN (99.1%) and stable controlled HTN (96.5%) upon validation.
  • Demonstrated strong interrater reliability with 91% agreement and Cohen's kappa of 0.87.

Conclusions:

  • Successfully constructed and validated computable phenotype algorithms for RHTN and stable controlled HTN.
  • Algorithms are based on the PCORnet CDM, facilitating broader application.
  • These validated phenotypes support future epidemiological and drug utilization research in hypertension.